Clinical trial NCT04616586: SILtuximab in Viral ARds (SILVAR) Study
Official title: A Study Comparing the Efficacy and Safety of Standard of Care With or Without Siltuximab in Selected Hospitalized Patients With Viral Acute Respiratory Distress Syndrome (SILVAR)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Acute Respiratory Distress Syndrome
Lung Diseases
Pneumonia
Respiratory Tract Infections
Respiratory Tract Disease
Keywords: Siltuximab
ARDS
Lead sponsor: RECORDATI GROUP
Sponsor class: INDUSTRY
Collaborators: name: Syneos Health
First posted: 2020-11-05
Enrollment: 555
Sex: ALL
Minimum age (years): 12
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a prospective, multicenter, randomized (2:1), double-blind, parallel-arm, placebo-controlled, Phase 3 clinical trial of 1-3 doses of siltuximab 11 mg/kg IV over 1 hour plus SOC vs. matched-volume normal saline (NS) IV over 1 hour plus SOC in 555 patients with SARS-CoV-2 previously treated with corticosteroids or another respiratory virus infection with elevated CRP levels who have developed serious respiratory complications
Primary purpose: TREATMENT

Brief summary: This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.

Detailed description: This is a prospective, multicenter, randomized (2:1), double-blind, parallel-arm, placebo-controlled, Phase 3 clinical trial of 1-3 doses of siltuximab 11 mg/kg IV over 1 hour plus SOC vs. matched-volume normal saline (NS) IV over 1 hour plus SOC in 555 patients with SARS CoV-2 previously treated with corticosteroids or another respiratory virus infection with elevated CRP levels who have developed serious respiratory complications.

The randomization will be stratified by age (\<65, ≥65 years), respiratory virus infection (confirmed SARS-CoV-2, other), and MIV status (yes, no). Crossover between treatment arms will not be allowed.

All patients will receive ARDS SOC following the official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine clinical practice guideline13 and/or the World Health Organization's (WHO's) clinical management of severe acute respiratory infection when COVID-19 disease is suspected (WHO Interim Guidance 202014 or other local guidance). Patients may continue receiving their corticosteroid (up to a cumulative maximum dexamethasone or equivalent dose of 60 mg \[except to treat treatment-emergent reactions or comorbid conditions\]) or antiviral therapy (except aminoquinoline compounds and convalescent plasma) at the same or lower doses if started at least 4 days (corticosteroid therapy) or at least 2 days (antiviral therapy) prior to randomization. Patients randomized to Arm A will additionally receive siltuximab 11 mg/kg IV administered over 1 hour, while patients randomized to Arm B will additionally receive IV NS administered over 1 hour, with opportunity to repeat their assigned study treatment once or twice at least 2 days apart on or after Day 3 as their clinical condition and/or laboratory testing dictate.

Eligibility criteria: Inclusion Criteria:

* Positive microbiological evidence of SARS-CoV-2 or another respiratory virus infection (eg, other coronaviruses, respiratory syncytial virus, influenza virus) following institutional diagnostic standards
* Clinical and radiological diagnosis of pulmonary infection requiring noninvasive or mechanical invasive ventilatory support plus administration of rising supplemental oxygen concentrations
* Treatment of SARS-CoV-2-infected patients with dexamethasone (or equivalent) administered by mouth or intravenous (IV) injection
* Diagnosis of ARDS (PaO2/FiO2 ≤200 with positive end-expiratory pressure ≥5 cmH2O) in accordance with Berlin 2012 criteria1 (measured on or after the fourth day after the start of corticosteroid therapy in those patients for whom it was prescribed)
* Serum CRP level greater than upper limit of normal (measured on or after the third day after the start of corticosteroid therapy in those patients for whom it was prescribed) on 2 consecutive days
* Age ≥12 years

Exclusion Criteria:

* Active bacterial or fungal infection, human immunodeficiency virus (HIV), HHV, Epstein-Barr virus, or other non-respiratory virus infection, or tuberculosis requiring initiation of anti-infective therapy
* Prior treatment with an agent targeting the IL-6 signaling pathway
* Current treatment in another therapeutic clinical trial (other than expanded remdesivir access protocol)
* Start of new immunosuppressive therapy (including but not limited to corticosteroids and cytokine signaling pathway inhibitors) within 4 days prior to study entry (randomization); start of new antiviral treatment (including but not limited to nucleoside analogues, aminoquinoline compounds, and convalescent plasma) within 2 days prior to randomization; or received a live vaccine at any time prior to randomization, or plan to receive a live vaccine during the study

Primary outcomes:
measure: 28-day all-cause mortality
timeFrame: Day 28
Secondary outcomes:
measure: Time to 7-category ordinal scale of clinical status improvement (T7COSCSI)
timeFrame: Up to 60 days
measure: Ventilator-free days (VFDs) within 28 days
timeFrame: Up to 28 days
measure: Organ failure-free days (OFFD)
timeFrame: Up to 60 days
measure: Intensive care unit length of stay (ICU LOS)
timeFrame: Up to 60 days
measure: Hospital length of stay (HLOS)
timeFrame: Up to 60 days
measure: In-hospital all-cause mortality (IHACM)
timeFrame: Up to 60 days
measure: 60-day all-cause mortality (60DACM)
timeFrame: Up to 60 days
measure: Time to oxygenation improvement (TOI)
timeFrame: Up to 60 days
measure: Duration of supplemental oxygen (DSO)
timeFrame: Up to 60 days
measure: Chest radiographic improvement (CRI)
timeFrame: Up to 60 days
measure: Time to National Early Warning Score 2 improvement (TNEWS2I)
timeFrame: Up to 60 days
measure: Treatment-emergent adverse events (TEAEs)
timeFrame: Up to 60 days
measure: Plasma siltuximab concentrations (PSCs)
timeFrame: Up to 60 days
measure: Anti-siltuximab antibodies (ASA)
timeFrame: Up to 60 days
Other outcomes:
Locations:
city: Lansing
country: United States
facility: Sparrow Clinical Research Institute
state: Michigan
city: Charlotte
country: United States
facility: Atrium Health
state: North Carolina
Study officials:
affiliation: Participating Site
name: Zainab Shahid, MD, Ph.D
role: PRINCIPAL_INVESTIGATOR
References: